Our Programs
ImmVue programs are built on the IMPAKT™ platform, designed to precisely tune intracellular immune signaling
Unlike traditional immune therapies that push the immune system broadly, IMPAKT molecules act at critical intracellular control points, allowing immune activity to be shaped with greater precision
Programs Built on Intracellular Immune Control
One platform. Two lead programs.
IMPAKT enables both immune activation and immune suppression from the same discovery architecture
IMPAKT-197 (Agonist)
Designed to enhance anti-tumor immunity; initial focus in solid tumors; combination logic with checkpoint-based approaches
IMPAKT-396 (Antagonist)
Therapeutic Pipeline
IMPAKT-197
ITK Agonist
Phase 1
IND-Enabling
Pre-Clinical
Late Discovery
IMPAKT-396
ITK Antagonist
Phase 1
IND-Enabling
Pre-Clinical
Late Discovery
Therapeutic Pipeline
IMPAKT-197 | ITK Agonist
IND-
Enabling
Pre-
Clinical
Late
Discovery
IMPAKT-396 | ITK Antagonist
IND-
Enabling
Pre-
Clinical
Late
Discovery
Why Current Approaches Fall Short
Traditional immunotherapies share a common limitation
Current immunotherapies do not directly target the intracellular TCR signaling machinery that determines T-cell activation strength. As a result, therapies must rely on indirect mechanisms that introduce trade-offs between efficacy, safety, and scalability
IMPAKT
Mechanism | First proven small-molecule ITK agonism; allosteric tunable, bidirectional
Structure/Design | Machine learning-driven
Format | Small molecules
Delivery | IV / Oral
Safety | Selective modulation of antigen-specific T cells
Modulation | Tunable immune control
Typical IO/Kinase or Legacy Biologics
Mechanism | Inhibition only / binary on-off
Structure/Design | Conventional MedChem or Antibody engineering
Format | Antibodies / Cell Therapy / Small Molecules
Delivery | IV / Oral / Cell therapy
Safety | Broad immune modulation
Modulation | Single-direction
IMPAKT
Typical IO/Kinase or Legacy Biologics
Mechanism
First proven small-molecule ITK agonism; allosteric tunable, bidirectional
Inhibition only / binary on-off
Structure/Design
Machine learning-driven
Conventional MedChem or Antibody engineering
Format
Small molecules
Antibodies / Cell Therapy /
Small Molecules
Delivery
IV / Oral
IV / Oral / Cell therapy
Safety
Selective modulation of
antigen-specific T cells
Broad immune modulation
Modulation
Tunable immune control
Single-direction